Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma:an open question

  • Letter to the Editor
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Licitra L, Felip E, ESMO Guidelines Working Group (2009) Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:121–122

    Article  PubMed  Google Scholar 

  3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  PubMed  CAS  Google Scholar 

  4. Frampton JE (2010) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 70:1987–2010

    Article  PubMed  CAS  Google Scholar 

  5. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  PubMed  CAS  Google Scholar 

  6. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177

    Article  PubMed  CAS  Google Scholar 

  7. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072–1078

    Article  PubMed  CAS  Google Scholar 

  8. Ley J, Mehan P, Wildes TM, Thorstad W, Gay HA, Michel L, Nussenbaum B, Trinkaus K, Adkins D (2013) Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology 85:290–296

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N (2011) Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:915–922

    Article  PubMed  CAS  Google Scholar 

  10. Giuliani J, Marzola M (2014) Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Cent Eur J Med 9:279–284

    CAS  Google Scholar 

  11. Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee TL, Chen MH, Yang MH, Chang PMH (2014) Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int 2014:904341

    PubMed  PubMed Central  Google Scholar 

  12. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA (2008) Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 7:676–681

    Article  Google Scholar 

  13. Levy AR, Johnston KM, Sambrook J, Donato B, Penrod JR, Corral M, Chasen M (2011) Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 27:2253–2259

    Article  PubMed  CAS  Google Scholar 

  14. Barni S, Coinu A, Borgonovo K, Cabiddu M, Cremonesi M, Petrelli F (2014) Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: a meta-analysis of published trials. J Clin Oncol 32:5

    Article  Google Scholar 

  15. Riaz N, Sherman EJ, Fury M, Nancy Lee N (2013) Should cetuximab replace cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? J Clin Oncol 31:287–288

    Article  PubMed  CAS  Google Scholar 

  16. Forastiere AA (2008) Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 97:701–707

    Article  PubMed  CAS  Google Scholar 

  17. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14

    Article  PubMed  Google Scholar 

  18. Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, Thirion P (2011) Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 98:38–41

    Article  PubMed  CAS  Google Scholar 

  19. Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK (2012) The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 12:517–528

    Article  PubMed  CAS  Google Scholar 

  20. Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C (2013) Adaptive and innovative radiation treatment FOR improving Cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer 13:84–92

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Oncology, ASL, 21 della Regione Veneto, Via Gianella, 37045, Legnago (VR), Italy

    Jacopo Giuliani & Andrea Bonetti

Authors
  1. Jacopo Giuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacopo Giuliani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giuliani, J., Bonetti, A. Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma:an open question. Eur Arch Otorhinolaryngol 273, 263–265 (2016). https://doi.org/10.1007/s00405-015-3562-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-015-3562-4

Keywords

Search

Navigation